Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DXR

Daxor Corp

Mar 18 • 04:00PM ET

8.05

Dollar change +0.08
Percentage change 1.00	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: BIO DHR BRKR TMO MMI QDEL A TRIB VRTX ILMN

| Held by: VTI

Scroll to Statements

Index	-	P/E	73.85	EPS (ttm)	0.11	Insider Own	5.30%	Shs Outstand	4.93M	Perf Week	3.38%
Market Cap	39.63M	Forward P/E	-	EPS next Y	-	Insider Trans	1.70%	Shs Float	2.12M	Perf Month	12.12%
Income	0.50M	PEG	-	EPS next Q	-	Inst Own	2.30%	Short Float	0.54%	Perf Quarter	-9.75%
Sales	0.10M	P/S	396.32	EPS this Y	87.90%	Inst Trans	18.28%	Short Ratio	1.75	Perf Half Y	-7.47%
Book/sh	7.25	P/B	1.11	EPS next Y	-	ROA	1.50%	Short Interest	0.01M	Perf Year	-3.59%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	1.50%	52W Range	6.55 - 10.00	Perf YTD	4.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.10%	ROI	-	52W High	-19.50%	Beta	-0.05
Dividend TTM	-	Quick Ratio	0.10	Sales past 5Y	-24.20%	Gross Margin	100.00%	52W Low	22.90%	ATR (14)	0.43
Dividend Ex-Date	Jan 05, 2018	Current Ratio	0.20	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	57.06	Volatility	6.79% 5.23%
Employees	-	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	23.38
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	-36.20%	Payout	0.00%	Rel Volume	3.23	Prev Close	7.97
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-41.80%	Earnings	-	Avg Volume	6.58K	Price	8.05
SMA20	4.69%	SMA50	3.45%	SMA200	-7.28%	Trades		Volume	20,384	Change	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-16-19	Initiated	Ascendiant Capital Markets	Buy	$20

Mar-04-25 04:55PM	Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 (GlobeNewswire)
03:53PM	Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 (GlobeNewswire)
09:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Feb-28-25 08:00AM	Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center (GlobeNewswire)
Feb-27-25 08:00AM	Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals (GlobeNewswire)
08:00AM	Loading…
Feb-19-25 08:00AM	Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025 (GlobeNewswire)
Feb-18-25 08:00AM	Daxor to Exhibit at World's Largest Critical Care Conference (GlobeNewswire)
Feb-14-25 08:00AM	Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment (GlobeNewswire)
Feb-13-25 08:00AM	New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care (GlobeNewswire)
Dec-18-24 08:00AM	Daxor Expands Its BVA-100 Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum (GlobeNewswire)
Oct-09-24 08:00AM	DAXOR'S INNOVATIVE BVA-100 BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 (GlobeNewswire)
Oct-08-24 08:00AM	Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-27-24 05:00PM	Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device (GlobeNewswire)
Sep-19-24 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 (GlobeNewswire)
Sep-12-24 08:00AM	Newly Published Review Highlights the Pivotal Role of Daxor's Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management (GlobeNewswire)
08:00AM	Loading…
Sep-05-24 08:00AM	Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee (GlobeNewswire)
Sep-04-24 08:30AM	Leading Central Florida Hospital Implements Daxor's BVA-100 Blood Volume Diagnostic for Heart Failure Patient Care (GlobeNewswire) +5.40%
Sep-03-24 04:05PM	Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter (GlobeNewswire)
12:15PM	Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 08:00AM	Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network (GlobeNewswire) +21.25%
Aug-06-24 08:00AM	Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Aug-05-24 08:00AM	Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide (GlobeNewswire) +11.96%
Jul-24-24 08:00AM	Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Jul-11-24 08:00AM	Daxor Corporation's BVA-100 Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide (GlobeNewswire)
Jun-18-24 08:00AM	Daxor Corporation to Showcase the Benefits of BVA-100 Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting (GlobeNewswire)
Jun-05-24 08:00AM	Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-16-24 08:00AM	New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion (GlobeNewswire)
Apr-15-24 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100 ) (GlobeNewswire)
Apr-10-24 08:00AM	Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital (GlobeNewswire)
Apr-01-24 08:00AM	Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 (GlobeNewswire)
10:38AM	Loading…
Mar-28-24 10:38AM	Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-25-24 08:00AM	Daxor Corporation Acquires Volumex and Megatope From Its Existing Supplier Along With Glofil to Enhance Existing Suite of Diagnostics (GlobeNewswire) +6.74%
Mar-22-24 08:00AM	Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 (GlobeNewswire)
Mar-18-24 02:18PM	Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 (GlobeNewswire)
02:18PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Mar-11-24 08:00AM	Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base (GlobeNewswire)
Mar-08-24 08:00AM	Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients (GlobeNewswire)
Feb-26-24 08:00AM	Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference (GlobeNewswire)
Feb-12-24 08:00AM	Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions (GlobeNewswire)
Feb-07-24 08:00AM	Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100 Blood Volume Diagnostic Across the U.S. at Existing Accounts (GlobeNewswire)
Jan-29-24 08:00AM	Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting (GlobeNewswire)
Jan-16-24 08:00AM	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress (GlobeNewswire)
Jan-09-24 08:00AM	DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES (GlobeNewswire)
Jan-02-24 08:30AM	Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer (GlobeNewswire)
Nov-13-23 08:00AM	New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients (GlobeNewswire) +7.05%
Nov-09-23 08:00AM	Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume (GlobeNewswire)
Oct-13-23 08:00AM	Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-11-23 08:00AM	New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100 Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 08:00AM	Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program (GlobeNewswire)
Sep-27-23 08:00AM	Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023 (GlobeNewswire)
Sep-26-23 08:00AM	DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXORS BLOOD VOLUME DIAGNOSTIC (BVA-100®) (GlobeNewswire)
Sep-11-23 12:00PM	Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients (GlobeNewswire)
Sep-07-23 09:15AM	Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-28-23 04:15PM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
04:05PM	Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023 (GlobeNewswire)
Aug-10-23 08:00AM	JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100® (GlobeNewswire)
Jul-12-23 08:00AM	JACC-HF Study Compares Daxors BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients (GlobeNewswire)
Jul-11-23 08:00AM	Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S. (GlobeNewswire)
Jul-05-23 08:00AM	Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer (GlobeNewswire)
Jun-22-23 04:15PM	Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering (GlobeNewswire)
Jun-20-23 08:00AM	Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting (GlobeNewswire)
Jun-15-23 08:00AM	Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services (GlobeNewswire)
Jun-12-23 08:00AM	Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-25-23 03:37PM	Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering (GlobeNewswire)
May-22-23 08:30AM	Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering (GlobeNewswire) -22.30%
May-19-23 04:53PM	Daxor Corporation Announces Proposed Underwritten Public Offering (GlobeNewswire) -6.06%
May-18-23 08:00AM	New Study Demonstrates Clinical Utility of Daxors Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes (GlobeNewswire)
Apr-20-23 08:00AM	New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure (GlobeNewswire)
Apr-17-23 08:00AM	Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring23 to Advance Awareness and Further Adoption of Daxors Blood Volume Diagnostic (BVA-100®) (GlobeNewswire)
Apr-13-23 08:00AM	Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions (GlobeNewswire)
Mar-27-23 08:00AM	Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients (GlobeNewswire) +15.89%
Mar-23-23 08:30AM	New Study Confirms Daxors BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients (GlobeNewswire)
08:00AM	Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients (GlobeNewswire)
Mar-03-23 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Mar-02-23 07:00AM	Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022 (GlobeNewswire) +5.46%
Mar-01-23 08:00AM	Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update (GlobeNewswire)
Feb-17-23 08:00AM	Daxor Corporation Appoints Linda Cooper, Vice President Project Management (GlobeNewswire)
Jan-19-23 08:00AM	Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member (GlobeNewswire)
Jan-13-23 08:00AM	Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress (GlobeNewswire) -6.22%
Jan-03-23 08:00AM	Newly Published Study Proves Value and Clinical Benefit of Daxors Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure (GlobeNewswire)
Nov-17-22 11:07AM	Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option (GlobeNewswire)
Nov-15-22 08:45AM	Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering (GlobeNewswire) -15.99%
Nov-14-22 05:03PM	Daxor Corporation Announces Launch of Proposed Underwritten Public Offering (GlobeNewswire)
Nov-10-22 08:00AM	Live Webinar by MedAxiom Features Best Practices Using Daxors Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs (GlobeNewswire)
Nov-03-22 08:00AM	Newly Published Study Demonstrates Significant Clinical Utility of Daxors Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure (GlobeNewswire)
Oct-31-22 08:00AM	Daxor Corporation to Exhibit at American Heart Associations Scientific Sessions 2022 (GlobeNewswire)
Oct-05-22 08:30AM	Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting (GlobeNewswire)
Oct-04-22 08:30AM	DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXORS BLOOD VOLUME DIAGNOSTIC (BVA-100®) (GlobeNewswire)
08:00AM	Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting (GlobeNewswire)
Oct-03-22 09:00AM	New Data Shows Heart Failure Treatment Guided by Daxors BVA-100® Lowers Hospital Length of Stay by 55% (GlobeNewswire)
08:40AM	New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care (GlobeNewswire)
08:00AM	New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures (GlobeNewswire)
Sep-26-22 08:00AM	Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America (GlobeNewswire)
Sep-06-22 05:05PM	Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-29-22 08:00AM	Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders (GlobeNewswire)
Aug-25-22 04:05PM	Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022 (GlobeNewswire) -8.55%
Aug-24-22 04:40PM	Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update (GlobeNewswire) +5.49%
Jul-27-22 08:00AM	Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S. (GlobeNewswire)
Jul-21-22 08:00AM	DAXOR CORPORATION ANNOUNCES PARTNERSHIP WITH MEDAXIOM TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXORS BLOOD VOLUME DIAGNOSTIC (BVA-100®) (GlobeNewswire)
Jul-18-22 08:00AM	DAXOR COMPLETES NIH FUNDED I-CORPS PROGRAM FOR COMMERCIALIZATION OF CLINICAL DECISION SUPPORT SOFTWARE (GlobeNewswire)

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michel Robert J	Chief Financial Officer	Mar 10 '25	Buy	8.00	1,000	8,000	17,050	Mar 11 09:36 AM
Feldschuh Michael Richard	Chief Executive Officer	Mar 10 '25	Buy	7.68	3,360	25,805	210,852	Mar 11 09:36 AM
Michel Robert J	Chief Financial Officer	Mar 27 '24	Buy	8.70	750	6,525	11,300	Mar 27 01:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DXR

Daxor Corp

Upgrade your FINVIZ experience